Development of six immune‐related lncRNA signature prognostic model for smoking‐positive lung adenocarcinoma

Abstract

Background Smoking is one of the most hazardous risk factors for the development of lung adenocarcinoma (LUAD). Many survival and prognosis‐related biomarkers were discovered using database mining. However, the precision of immune‐related long noncoding RNAs (lncRNAs) predictions is insufficient. We identified a novel signature to improve the estimate of smoking‐related LUAD prognosis. Methods The Cancer Genome Atlas database (TCGA) was used to obtain the LUAD lncRNA expression profiles. The smoking‐related LUAD cohort was randomly split into discovery and validation cohorts. To determine the risk score, use the LASSO Cox regression technique on the prognostic immune‐related lncRNA. The risk signature has been developed. Results A total of 643 immune‐related lncRNAs were identified as potential candidates for a risk signature. Finally, six immune‐related lncRNAs (AL359915.2, AP000695.1, HSPC324, TGFB2‐AS1, AC026355.1, and AC002128.2) were identified and used to carry out risk signature, which showed a close association with overall survival in the discovery cohort. We classified patients as high risk or low risk based on a median risk score of 1.0783. In the discovery cohort, overall survival was marginally longer in the low‐risk group than in the high‐risk category ( p = 2.28e08). The area under the curves (AUC) for 1‐, 3‐, and 5‐year survival was 0.67, 0.7, and 0.82, respectively. Furthermore, we successfully validated and combined cohorts using this risk profile. We discovered a strong positive connection between HSPC324 and VIPR1 as a possible novel biomarker for smoking‐related LUAD development in our study. Conclusions Our research has established a six immune‐lncRNA signature that may be used to predict the prognosis of smoking‐related LUAD with great accuracy.

Prediction of Prognosis and Chemotherapeutic Sensitivity Based on Cuproptosis-Associated lncRNAs in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma

“…Previous studies also found that these markers can indeed be used as markers of cancer. For example, Zhou et al found that AC002128.2 could be the prognostic biomarker for lung adenocarcinoma [38]. Zhang, Liang, Chen, et al found that AC009237.14 could be the prognostic biomarker for colon adenocarcinoma [39][40][41].…”

Cuproptosis-related lncRNAs signature as a potential predictor biomarker for prognosis and immune response in LUAD patients

“…AC026355.2 has been reported to play an important role in the prognosis of LUAD [28,29]. AP000695.1 has been reported to play a role in the prognosis of LUAD and gastric cancer [30,31]. ARHGEF26-AS1 is a gene closely related to biological oxidative stress and immune response, which may be a target for the early diagnosis and treatment of Osteoarthritis [32].…”

Comprehensive analysis of m6A modification patterns and m6A‐related lncRNAs as potential biomarkers in lung adenocarcinoma

“…This indicate that lncRNAs could potentially function as indicators for predicting, diagnosing, and prognosing lung cancer 16 . While the prognostic significance of lncRNAs has been documented in lung cancer prognosis, 17,18 there has been relatively limited research on the prognostic implications of lncRNAs linked to m6A methylation in LUAD. Hence, it is worth exploring the potential of m6A methylation‐related lncRNAs as novel biomarkers for prognostic evaluation in LUAD patients.…”